O’Melveny Represents RemeGen in its A-share IPO and Listing on SSE STAR Market
March 31, 2022
FOR IMMEDIATE RELEASE
SHANGHAI, March 31, 2022 — O’Melveny represented RemeGen Co., Ltd. (“RemeGen”) (9995.HK; 688331.SH) as its Hong Kong legal advisor in its A-share listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange. The A-share listing was completed today and RemeGen raised approximately RMB2.6 billion (approximately US$412 million) from the transaction. Huatai United Securities Co., Ltd. and J.P. Morgan Securities (China) Company Limited acted as the joint underwriters for the A-share listing.
RemeGen is one of the few Chapter 18A biotech issuers listed on the Hong Kong Stock Exchange that has successfully completed a first-H-then-A-share listing to date. Prior to its A-share listing, RemeGen completed the implementation of its H-share full circulation program to convert its unlisted shares into fully circulated H-shares for listing and trading on the Hong Kong Stock Exchange in June 2021. Being an A+H dual-listed issuer now, RemeGen can enjoy full access to China A-share investors while continuing to leverage Hong Kong as the international platform for its global branding, licensing, M&A and multi-national business cooperation.
O’Melveny previously represented RemeGen in its primary listing on the Hong Kong Stock Exchange, which was recognized as “Deal of the Year” by China Business Law Journal and “Megatrend Deal of the Year – Healthcare” by FinanceAsia. Last year, O’Melveny represented RemeGen in entering into an exclusive worldwide license agreement with Seagen Inc., a global biotechnology company, to develop and commercialize RemeGen’s disitamab vedotin (RC48, Brand Name: 爱地希®), as well as the adoption and implementation of its H-share full circulation program.
The O’Melveny team for the A-share listing of RemeGen was led by Hong Kong corporate partner Edwin Kwok, with support from Hong Kong corporate counsel Wendy Kan and associate Michelle Ye.
About O’Melveny
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com or learn more in our firm at-a-glance, year-end highlights, and on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
Contact:
Christopher Rieck
O’Melveny & Myers LLP
+1 212 326 2218
crieck@omm.com
Chris Schob
O’Melveny & Myers LLP
+86 21 2307 7000
cschob@omm.com